French Innovative Leukemia Organisation

This study tests a two-drug combination (tagraxofusp and venetoclax) in adults with a rare and aggressive blood cancer called BPDCN who have not had prior treatment. The main goal is to see if the combination can achieve complete remission after 3 months. Depending on results, pa…

This study tests a new drug called glofitamab, given with standard chemotherapy, for people with untreated Richter syndrome (an aggressive lymphoma that develops from chronic lymphocytic leukemia). The goal is to see if this combination can shrink or eliminate the cancer. About 4…

This study observes 250 adults with a specific genetic subtype of acute myeloid leukemia (AML) who received the targeted drug Ivosidenib through a compassionate use program in France. Researchers will track survival and treatment response in patients receiving the drug as a first…

This study gathers information from 50 people with T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive blood cancer. Researchers will look at patients' medical records, lab results, and genetic data to better understand the disease and how it responds to current treatme…

This study looks at 500 people with Waldenström macroglobulinemia, a rare blood cancer, to check how well current scoring systems predict survival and treatment response. Researchers will track patients over time, including those without symptoms, to refine these tools. The goal …